search
Back to results

Evaluation the Treatment of Nonunion of Long Bone Fracture of Lower Extremities (Femur and Tibia) Using Mononuclear Stem Cells From the Iliac Wing Within a 3-D Tissue Engineered Scaffold

Primary Purpose

Nonunion of Fracture

Status
Unknown status
Phase
Phase 2
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold
Sponsored by
Emdadi Kamyab Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nonunion of Fracture focused on measuring nonunion, mesenchymal stem cell, scaffold, BMP2, long bone

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Every patient with non union in the site of long bone fracture
  • Age more than 18 and under 60 years old
  • Fracture having no radiological callus after 6 months and absence of any hypertrophic bone reaction.
  • No infection in site of surgery
  • Be able and willing to participate in the study
  • Written informed consent

Exclusion Criteria:

  • Evidence of malignancy
  • Pregnancy or breastfeeding
  • Patient positive by serology or PCR for HIV, hepatitis B or C infection the patient with Accompanied fracture such as hip fracture that could not weight bearing

Sites / Locations

  • Emdai Kamyab HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

mesenchymal stem cell

Arm Description

stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.

Outcomes

Primary Outcome Measures

clinical and radiological union at 1 month to 6 months
patients receiving Mesenchymal Stem Cells within a 3-D tissue engineered scaffold that develop a partial or complete callus at 1, 2, 3, 4 ,5 and 6 months evaluate with standard X-rays

Secondary Outcome Measures

Safety of Mesenchymal Stem Cells injection in nonunion fractures. Follow-up for revealing any significant immediate or late adverse effects(infection,malignancy,local or systemic allergic reaction)

Full Information

First Posted
August 21, 2013
Last Updated
October 8, 2013
Sponsor
Emdadi Kamyab Hospital
Collaborators
National Taiwan University of Science and Technology
search

1. Study Identification

Unique Protocol Identification Number
NCT01958502
Brief Title
Evaluation the Treatment of Nonunion of Long Bone Fracture of Lower Extremities (Femur and Tibia) Using Mononuclear Stem Cells From the Iliac Wing Within a 3-D Tissue Engineered Scaffold
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Unknown status
Study Start Date
July 2013 (undefined)
Primary Completion Date
July 2014 (Anticipated)
Study Completion Date
November 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Emdadi Kamyab Hospital
Collaborators
National Taiwan University of Science and Technology

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Because the rate of non union of long bone in lower extremities specially in tibia in this two last decade due to malnutrition and smoking and other risk factors was increased, so many patient in our country suffer from non union. On the other hand it seems that the use of the mesenchymal stem cells can irritate the union rate. Also for better result we used the mesenchymal stem cells with BMP2 in collagenic scaffold. The collagen has a osteoconductive effect and BMP2 and stem cells has a osteoinductive effect therefore this combination is useful in filling the gap in non union site and irritate the union rate. Mesenchymal stem cell derived from iliac bone marrow after centrifuge with ficoll procedure. Then the investigators will follow the patient with monthly radiography and evaluate the callus volume and clinical union and any side effect of this treatment. Clinical union consider to relief pain in non union site and be stable in examination.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nonunion of Fracture
Keywords
nonunion, mesenchymal stem cell, scaffold, BMP2, long bone

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
18 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
mesenchymal stem cell
Arm Type
Experimental
Arm Description
stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.
Intervention Type
Genetic
Intervention Name(s)
surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold
Primary Outcome Measure Information:
Title
clinical and radiological union at 1 month to 6 months
Description
patients receiving Mesenchymal Stem Cells within a 3-D tissue engineered scaffold that develop a partial or complete callus at 1, 2, 3, 4 ,5 and 6 months evaluate with standard X-rays
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Safety of Mesenchymal Stem Cells injection in nonunion fractures. Follow-up for revealing any significant immediate or late adverse effects(infection,malignancy,local or systemic allergic reaction)
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Every patient with non union in the site of long bone fracture Age more than 18 and under 60 years old Fracture having no radiological callus after 6 months and absence of any hypertrophic bone reaction. No infection in site of surgery Be able and willing to participate in the study Written informed consent Exclusion Criteria: Evidence of malignancy Pregnancy or breastfeeding Patient positive by serology or PCR for HIV, hepatitis B or C infection the patient with Accompanied fracture such as hip fracture that could not weight bearing
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
mohammad taghi peivandi, MD
Phone
+989153143691
Email
peivandimt@mums.ac.ir
First Name & Middle Initial & Last Name or Official Title & Degree
Amin razi, MD
Phone
+989153118713
Email
aminra61@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
mohammad taghi peivandi, MD
Organizational Affiliation
Emdadi Kamyab Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
amin razi, MD
Organizational Affiliation
Emdadi Kamyab Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Emdai Kamyab Hospital
City
Mashhad
State/Province
Khorasan
Country
Iran, Islamic Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
mohammad taghi peivandi, MD
Phone
989153143691
Email
peivandimt@mums.ac.ir
First Name & Middle Initial & Last Name & Degree
amin razi, MD
Phone
989153118713
Email
aminra61@gmail.com
First Name & Middle Initial & Last Name & Degree
bibi fatemeh kalalinia, PHD
First Name & Middle Initial & Last Name & Degree
hosein hoseinkhani, PHD
First Name & Middle Initial & Last Name & Degree
sara amel farzad, MD

12. IPD Sharing Statement

Learn more about this trial

Evaluation the Treatment of Nonunion of Long Bone Fracture of Lower Extremities (Femur and Tibia) Using Mononuclear Stem Cells From the Iliac Wing Within a 3-D Tissue Engineered Scaffold

We'll reach out to this number within 24 hrs